The mutated genes identified in the ten other patients (ATM, CDKN2A, CHEK2, FH, MUTYH, RAD51D, and RECQL) had not been previously analyzed due to the absence of recommendation for sequencing at the time of oncogenetics consultation (RAD51D) and/or for clinical management in breast and/or ovarian cancer predisposition (other genes). This evidence concerns the gene RECQL and ovarian carcinoma.